In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Years of translational research have successfully improved treatment outcomes for common dermatological conditions such as ...

The intestinal epithelium is a highly dynamic barrier that regulates digestion, absorption, immune responses, and ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Ruby Tsang summarises a recent longitudinal study of trajectories of inflammation in youth and risk of mental and ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Researchers found that while sweat biomarkers remain stable, plasma biomarkers show significant inflammatory changes after a ...